literature

HIV mutation literature information.

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

PMID: 18444871 2008 Clinical infectious diseases

Abstract: The previously undescribed mutational pattern K65R/G190S/Y181C was observed in 6 of 21 patients treated with efavirenz and TDF.

HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso.

PMID: 18667925 2008 Journal of acquired immune deficiency syndromes (1999)

Abstract: Dominant mutations included M46I (37%), 154V (26%), V82A/T/F (30%) in PR; K103N (44%), G190A/S (16%) and T215F/Y (48%) (NRTIs) in RT.

Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

PMID: 18844463 2008 AIDS research and human retroviruses

Abstract: K101E and G190S together tend to decrease susceptibility to all nucleoside RT inhibitors, but the K103N mutation had little effect on nucleoside RT inhibitor susceptibility.

Abstract: In virus strains with the nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations K101E and G190S, the L74V mutation increased replication capacity, consistent with published observations, but replication capacity was decreased in strains without NNRTI resistance mutations.

Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.

PMID: 18855659 2008 Current HIV research

Abstract: We focused on etravirine-RAMs previously described: V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, and G190A/S.

HIV drug resistance tendencies in Latvia.

PMID: 18935781 2008 Central European journal of public health

Abstract: In the group of NRTI mutations M184V (26/75; 34.6%), A62V (12/75; 16.0%) and T215Y (8/75; 10.6%), in NNRTI mutations K103N (10/75; 13.3%), G190S (6/75; 8.0%), in PI group mutations L90M (6/75; 8.0%) and M461/L (6/75; 8.0%) occurred most frequently.

Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.

PMID: 19043929 2008 Antiviral therapy

Abstract: Emergence of resistant variants (including K103N, Y181C or G190S) after interruption was associated with a higher coefficient of variation in NNRTI plasma concentrations during the treatment period.

Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.

PMID: 19124911 2008 Georgian medical news

Abstract: G190S/A was the most frequent NNRTI mutation (42.2%), followed by K103N (28.9%).

Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.

PMID: 19881888 2008 Future HIV therapy

Conclusion: Etravirine RAMs include V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L.

Introduction: Of the mutations that had most significantly affected response to etravirine in the DUET trials, Y181C was present in 17.5% of the isolates, G190S in less than 2.5%, and V179F was not found in any isolates.

Table: G190S

Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients.

PMID: 17306618 2007 Journal of clinical virology

Abstract: RESULTS: Direct sequencing of DNA provirus disclosed key mutations (such as G190A/S, V106A, K103N and T215F) to RT inhibitors more frequently (7 patients out 31) than in plasma RNA (2 out of 31).

HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

PMID: 17500586 2007 PLoS computational biology

Method: NNRTI-selected mutations included A98G, L100I, K101E/P/N/H, K103N/S, V106A/M, V108I, V179D/E, Y181C/I/V, Y188L/C/H, G190A/S/E/Q, P225H, F227L, M230L, P236L, and K238T.

Browser Board

Co-occurred Entities

Filtrator